Education
About Us
Working with TipRanks
Follow Us
DWAS - ETF AI Analysis
Top Page
Invesco DWA SmallCap Momentum ETF (DWAS)
Rating:59Neutral
Price Target:
$93.00
Positive Factors
Strong Top Holdings
Several top holdings, such as Centrus Energy and BitMine Immersion Technologies, have delivered strong year-to-date performance, supporting the ETF’s overall returns.
Momentum Strategy
The ETF focuses on small-cap stocks with strong momentum, which can lead to higher growth potential in favorable market conditions.
Sector Diversification
The fund is spread across multiple sectors, including Health Care, Technology, and Industrials, reducing reliance on any single industry.
Negative Factors
High Expense Ratio
The ETF’s expense ratio of 0.6% is higher than many passive funds, which could eat into long-term returns.
Overwhelming U.S. Exposure
With nearly 100% of its assets in U.S. companies, the ETF lacks geographic diversification and is vulnerable to domestic market downturns.
Volatility Risk
Small-cap stocks are inherently more volatile, which could lead to larger swings in the ETF’s performance during market turbulence.
DWAS vs. SPDR S&P 500 ETF (SPY)
AUM680.86M
RegionNorth America
Expense Ratio0.60%
Beta1.23
IssuerInvesco
Inception DateJul 19, 2012
Dividend Yield0.15%
Asset ClassEquity
Index TrackedDorsey Wright SmallCap Tech Leaders Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume25,646
30 Day Avg. Volume20,034
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
116.19Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering205
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DWAS Summary
The Invesco DWA SmallCap Momentum ETF (DWAS) is an investment fund that focuses on small companies in the U.S. with strong momentum, meaning their stock prices have been rising quickly. It follows the Dorsey Wright SmallCap Technical Leaders Index, which picks companies showing solid growth trends. Some of its top holdings include Amprius Technologies and Centrus Energy. Investors might consider DWAS if they’re looking for growth opportunities and want to diversify into smaller, fast-moving companies. However, it’s important to know that small-cap stocks can be more volatile, meaning their prices can go up and down more dramatically than larger companies.
How much will it cost me?The Invesco DWA SmallCap Momentum ETF (DWAS) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on small-cap stocks with strong momentum, which requires more research and management compared to passively managed ETFs. It’s designed for investors seeking growth opportunities in dynamic, smaller companies.
What would affect this ETF?The DWAS ETF, focused on U.S. small-cap stocks with strong momentum, could benefit from economic growth and innovation in sectors like Health Care and Technology, which make up a significant portion of its holdings. However, it may face challenges during periods of economic uncertainty or rising interest rates, which can negatively impact small-cap companies and momentum-driven strategies. Regulatory changes or sector-specific headwinds could also influence the performance of its top holdings.
DWAS Top 10 Holdings
The Invesco DWA SmallCap Momentum ETF (DWAS) is leaning heavily into healthcare, with nearly 28% of its portfolio tied to the sector. Stocks like Cidara Therapeutics and Cogent Biosciences are rising stars, showing strong momentum and driving performance, while others like Amylyx Pharmaceuticals are lagging due to operational challenges. Technology also plays a notable role, but mixed signals from names like Amprius Technologies suggest uneven footing. With its focus on U.S. small-cap stocks, DWAS is a high-energy fund that thrives on momentum but faces risks from the volatility inherent in smaller companies.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Cidara Therapeutics | 3.16% | $22.15M | $6.90B | 975.24% | 57 Neutral | |
| Bel Fuse Inc | 1.27% | $8.87M | $1.74B | 77.50% | 55 Neutral | |
| Amprius Technologies Inc | 1.24% | $8.69M | $1.32B | 421.13% | 51 Neutral | |
| Terns Pharmaceuticals | 1.23% | $8.62M | $2.37B | 354.49% | 45 Neutral | |
| Amylyx Pharmaceuticals Inc | 1.21% | $8.51M | $1.61B | 178.37% | 52 Neutral | |
| Ondas Holdings | 1.20% | $8.39M | $2.48B | 659.30% | 49 Neutral | |
| Tutor Perini | 1.16% | $8.12M | $3.21B | 113.67% | 63 Neutral | |
| Celcuity | 1.13% | $7.89M | $4.51B | 639.20% | 44 Neutral | |
| Tango Therapeutics | 1.12% | $7.86M | $1.35B | 155.87% | 51 Neutral | |
| Cogent Biosciences | 1.09% | $7.67M | $5.59B | 302.63% | 37 Underperform |
DWAS Technical Analysis
Positive
―
Price Trends
92.80
Negative
89.69
Positive
85.28
Positive
Market Momentum
-0.72
Positive
47.48
Neutral
32.39
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For DWAS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 92.30, equal to the 50-day MA of 92.80, and equal to the 200-day MA of 85.28, indicating a neutral trend. The MACD of -0.72 indicates Positive momentum. The RSI at 47.48 is Neutral, neither overbought nor oversold. The STOCH value of 32.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DWAS.
DWAS Peer Comparison
Comparison Results
Performance Comparison
DWAS
Invesco DWA SmallCap Momentum ETF
91.21
-12.00
-11.63%
OUSM
OShares U.S. Small-Cap Quality Dividend ETF
―
―
―
FYX
First Trust Small Cap Core AlphaDEX Fund
―
―
―
GSSC
Goldman Sachs Activebeta U.S. Small Cap Equity ETF
―
―
―
SMDV
ProShares Russell 2000 Dividend Growers ETF
―
―
―
JHSC
John Hancock Multifactor Small Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents